11/4/2023 0 Comments Jing li one foundatonThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: The authors have declared that no competing interests exist.īenign prostatic hyperplasia (BPH) is a common disease in middle and old aged men and may significantly affect the quality of life. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper.įunding: Project was supported by grants from the National Natural Sciences Foundation of China (81425024, 81573442), "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences, Grant (XDA12040212), Shanghai Commission of Science and Technology (16431901500), the National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" (2017ZX09101004-012-008), and Institutes for Drug Discovery and Development, Chinese Academy of Sciences (CASIMM0120151007). Received: DecemAccepted: JanuPublished: January 19, 2018Ĭopyright: © 2018 Li et al. McCormick, IIT Research Institute, UNITED STATES The results demonstrate that testosterone-induced BPH rat and dog models might provide a more efficient way to evaluate micturition behavior in anti-BPH drug studies.Ĭitation: Li J, Tian Y, Guo S, Gu H, Yuan Q, Xie X (2018) Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. Silodosin, an α1-AR antagonist, significantly reduces the urinary frequency and increases the voided volume in BPH model animals in a dose-dependent manner. The BPH rats and dogs induced by chronic testosterone treatment have significantly increased micturition frequency and reduced mean voided volume, very similar to the clinical symptoms of BPH patients. Here we describe the development of testosterone-induced BPH models in both rats and young adult dogs and their applications in the in vivo evaluation of α1-AR antagonist. So it is necessary to develop more accessible animal models for drug efficacy evaluation. However, old dogs (>6 years) are expensive and not all old dogs develop BPH. In drug development, old male dogs with spontaneous BPH are considered the golden standard of the animal models. Currently, α 1-adrenergic receptor (α 1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms in voiding. Medical management of BPH is an alternative to surgical treatment of this disease. Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |